An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma

An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma

Archaeosomes constitute archaeal lipid vesicle vaccine adjuvants that evoke a strong CD8+ T cell response to antigenic cargo. Therapeutic treatment of murine B16-ovalbumin (B16-OVA) melanoma with archaeosome-OVA eliminates small subcutaneous solid tumors; however, they eventually resurge despite an...

Full description

Bibliographic Details
Main Authors:	Felicity C. Stark, Risini D. Weeratna, Lise Deschatelets, Komal Gurnani, Renu Dudani, Michael J. McCluskie, Lakshmi Krishnan
Format:	Article
Language:	English
Published:	MDPI AG 2017-10-01
Series:	Vaccines
Subjects:	checkpoint inhibitor PD-1 PD-L1 CTLA-4 tumor-infiltrating lymphocyte (TIL) cancer vaccine CD8+ T cell response archaeosome prime-boost B16 liposome tumor vaccine effector T cell (TE) effector memory T cell (TEM)
Online Access:	https://www.mdpi.com/2076-393X/5/4/38

Similar Items

Homologous Prime-Boost Vaccination with OVA Entrapped in Self-Adjuvanting Archaeosomes Induces High Numbers of OVA-Specific CD8+ T Cells that Protect Against Subcutaneous B16-OVA Melanoma
by: Felicity C. Stark, et al.
Published: (2016-11-01)

The Synergistic Effects of Sulfated Lactosyl Archaeol Archaeosomes When Combined with Different Adjuvants in a Murine Model
by: Yimei Jia, et al.
Published: (2021-02-01)

Sulfated archaeal glycolipid archaeosomes as a safe and effective vaccine adjuvant for induction of cell-mediated immunity
by: Michael J. McCluskie, et al.
Published: (2017-12-01)

Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model
by: Bassel Akache, et al.
Published: (2021-02-01)

Safety and biodistribution of sulfated archaeal glycolipid archaeosomes as vaccine adjuvants
by: Bassel Akache, et al.
Published: (2018-07-01)

Evaluation of Adjuvant Activity and Bio-Distribution of Archaeosomes Prepared Using Microfluidic Technology
by: Yimei Jia, et al.
Published: (2022-10-01)

Mechanistic insight into the induction of cellular immune responses by encapsulated and admixed archaeosome-based vaccine formulations
by: Gerard Agbayani, et al.
Published: (2020-09-01)

Adjuvanted Schistosoma mansoni-Cathepsin B With Sulfated Lactosyl Archaeol Archaeosomes or AddaVax™ Provides Protection in a Pre-Clinical Schistosomiasis Model
by: Dilhan J. Perera, et al.
Published: (2020-11-01)

Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
by: Tao Xia, et al.
Published: (2022-03-01)

Archaeosomes and Gas Vesicles as Tools for Vaccine Development
by: Natalia Adamiak, et al.
Published: (2021-09-01)

Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors
by: Renata Boldrini, et al.
Published: (2019-02-01)

Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern
by: Tyler M. Renner, et al.
Published: (2023-04-01)

T Cell Memory to Vaccination
by: Stephen M. Todryk
Published: (2018-12-01)

Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model
by: Yi-Ru Pan, et al.
Published: (2020-11-01)

PD-L1 Overexpression, SWI/SNF Complex Deregulation, and Profound Transcriptomic Changes Characterize Cancer-Dependent Exhaustion of Persistently Activated CD4<sup>+</sup> T Cells
by: Iga Jancewicz, et al.
Published: (2021-08-01)

Synthesis of Paclitaxel Loaded on Nanoparticles of Archaeosomes and Investigation of Its Anti-cancer Properties
by: Maral Mazloumi Tabrizi, et al.
Published: (2017-09-01)

Simultaneous and Spatially-Resolved Analysis of T-Lymphocytes, Macrophages and PD-L1 Immune Checkpoint in Rare Cancers
by: Karina Cereceda, et al.
Published: (2022-06-01)

Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma
by: Li-ming Zhao, et al.
Published: (2023-03-01)

Modulation of innate immune mechanisms to enhance vaccine induced immunity: Role of co-inhibitory molecules
by: Sreenivas eGannavaram, et al.
Published: (2016-05-01)

Can Immune Suppression and Epigenome Regulation in Placenta Offer Novel Insights into Cancer Immune Evasion and Immunotherapy Resistance?
by: Sultana Mehbuba Hossain, et al.
Published: (2021-07-01)

Evaluation of pd-1, pd-l1, and cytotoxic T-lymphocyteassociated protein 4 expressions together with clinicopathological findings in clear cell, papillary, and chromophobe types of renal cell carcinoma
by: Merve Inceman, et al.
Published: (2022-12-01)

Changes in Frequency and Activation Status of Major CD4+ T-Cell Subsets after Initiation of Immunosuppressive Therapy in a Patient with New Diagnosis Childhood-Onset Systemic Lupus Erythematosus
by: Saimun Singla, et al.
Published: (2017-05-01)

Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma
by: Yixiao Qin, et al.
Published: (2021-03-01)

Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy
by: Benjamin Rolles, et al.
Published: (2021-08-01)

Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer
by: Tian Zhang, et al.
Published: (2021-02-01)

A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice
by: Jiayi Pan, et al.
Published: (2022-07-01)

Immunotherapy for Prostate Cancer: Where We Are Headed
by: Giuseppe Schepisi, et al.
Published: (2017-12-01)

Curcumin as an Adjuvant to Cancer Immunotherapy
by: Silpita Paul, et al.
Published: (2021-08-01)

Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancer
by: Nikita Dutta, et al.
Published: (2023-02-01)

The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors
by: Konstantinos Evmorfopoulos, et al.
Published: (2024-01-01)

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
by: Carlo Genova, et al.
Published: (2022-01-01)

High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
by: Baran Mollavelioglu, et al.
Published: (2022-10-01)

Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors
by: Haiyue Wang, et al.
Published: (2018-05-01)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
by: Yiru Long, et al.
Published: (2022-05-01)

Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
by: Seyed Hossein Kiaie, et al.
Published: (2023-09-01)

The role of LncRNAs in tumor immunotherapy
by: Xuan Pan, et al.
Published: (2023-02-01)

Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition
by: Roger J. Daly, et al.
Published: (2022-09-01)

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
by: Chongxian Pan, et al.
Published: (2020-04-01)

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
by: Pauline Weimer, et al.
Published: (2022-03-01)

Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells
by: Krzysztof Piersiala, et al.
Published: (2022-09-01)